Formulation for treating obesity and associated metabolic syndrome

Details for Australian Patent Application No. 2005205031 (hide)

Owner Multipharma I Goteborg AB

Inventors Krotkiewski, Marcin

Agent Freehills

Pub. Number AU-A-2005205031

PCT Pub. Number WO2005/067952

Priority P.364411 15.01.04 PL

Filing date 12 January 2005

Wipo publication date 28 July 2005

International Classifications

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

Event Publications

20 July 2006 PCT application entered the National Phase

  PCT publication WO2005/067952 Priority application(s): WO2005/067952

7 February 2008 Assignment before Grant

  Bringwell International AB The application has been assigned to Scandinavian Clinical Nutrition i Sverige AB

4 August 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005205032-Method and device for mixing at least two fluids in a stirred tank microreactor

2005205016-1-benzyl-5-piperazin-1-yl-3,4 dihydro1H-quinazolin-2-one derivatives and the respective 1H-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(D) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-HT) for the treatment of diseases of the central nervous system